The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | How does a patient’s personal situation affect CLL treatment choice?
Barbara Eichhorst, MD, from the University of Cologne, Cologne, Germany, speaks about the influence of a patient’s personal situation on chronic lymphocytic leukemia (CLL) treatment choice at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She discusses aspects including travel time to the medical center, underlying comorbidities and tolerability of intravenous infusions. Dr Eichhorst also highlights that it is also important to consider subsequent treatment options.
